Recent studies have explored various strategies for developing effective aldose reductase inhibitors (ARIs) that can selectively target this enzyme while minimizing side effects. Recent research ...

The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease.